Flinton Capital Management LLC decreased its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 42.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 3,008 shares of the biotechnology company’s stock after selling 2,208 shares during the period. Flinton Capital Management LLC’s holdings in Ascendis Pharma A/S were worth $188,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. FMR LLC increased its position in Ascendis Pharma A/S by 24.3% during the 3rd quarter. FMR LLC now owns 4,152,262 shares of the biotechnology company’s stock worth $294,230,000 after purchasing an additional 812,468 shares during the period. Alliancebernstein L.P. increased its position in Ascendis Pharma A/S by 2.7% during the 3rd quarter. Alliancebernstein L.P. now owns 714,366 shares of the biotechnology company’s stock worth $50,620,000 after purchasing an additional 19,039 shares during the period. Marshall Wace North America L.P. increased its position in Ascendis Pharma A/S by 9.9% during the 3rd quarter. Marshall Wace North America L.P. now owns 703,087 shares of the biotechnology company’s stock worth $49,821,000 after purchasing an additional 63,540 shares during the period. Franklin Resources Inc. increased its position in Ascendis Pharma A/S by 7.8% during the 3rd quarter. Franklin Resources Inc. now owns 591,898 shares of the biotechnology company’s stock worth $41,942,000 after purchasing an additional 42,800 shares during the period. Finally, BlackRock Inc. increased its position in Ascendis Pharma A/S by 5.1% during the 3rd quarter. BlackRock Inc. now owns 460,961 shares of the biotechnology company’s stock worth $32,663,000 after purchasing an additional 22,172 shares during the period. Institutional investors own 95.41% of the company’s stock.

ASND has been the topic of several recent analyst reports. Wedbush set a $81.00 target price on Ascendis Pharma A/S and gave the stock a “buy” rating in a research report on Friday, January 25th. Zacks Investment Research upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating and set a $83.00 price target on the stock in a report on Friday, January 25th. BidaskClub upgraded Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Tuesday, December 18th. Leerink Swann upgraded Ascendis Pharma A/S from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $73.00 to $90.00 in a report on Thursday, January 24th. Finally, Credit Suisse Group upped their price target on Ascendis Pharma A/S from $80.00 to $86.00 and gave the stock an “outperform” rating in a report on Thursday, November 29th. One analyst has rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $123.67.

ASND opened at $128.19 on Friday. The company has a market capitalization of $5.39 billion, a P/E ratio of -29.61 and a beta of 0.91. Ascendis Pharma A/S has a 1-year low of $53.21 and a 1-year high of $131.76.

COPYRIGHT VIOLATION NOTICE: “Ascendis Pharma A/S (ASND) Holdings Cut by Flinton Capital Management LLC” was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://theolympiareport.com/2019/03/17/ascendis-pharma-a-s-asnd-holdings-cut-by-flinton-capital-management-llc.html.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Featured Story: Is it better to buy a fund with a higher or lower NAV?

Want to see what other hedge funds are holding ASND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ascendis Pharma A/S (NASDAQ:ASND).

Institutional Ownership by Quarter for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.